Online inquiry

IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14224MR)

This product GTTS-WQ14224MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14224MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14731MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ4027MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ4626MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ4982MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ6365MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ1181MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ8610MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ7042MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab C225
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW